Intractable hypercalcaemia during pregnancy and the postpartum secondary to pathogenic variants in CYP24A1
Parathyroid-independent hypercalcaemia of pregnancy, due to biallelic loss of function of the P450 enzyme CYP24A1, the principal inactivator of 1,25(OH)2D results in hypervitaminosis D, hypercalcaemia and hypercalciuria. We report two cases of this disorder, with intractable hypercalcaemia, one occu...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2019-11-01
|
Series: | Endocrinology, Diabetes & Metabolism Case Reports |
Online Access: | https://edm.bioscientifica.com/view/journals/edm/2019/1/EDM19-0114.xml |
id |
doaj-499fa2f358bf4986bfc6fc4625fd35e7 |
---|---|
record_format |
Article |
spelling |
doaj-499fa2f358bf4986bfc6fc4625fd35e72020-11-25T01:34:39ZengBioscientificaEndocrinology, Diabetes & Metabolism Case Reports2052-05732052-05732019-11-01111610.1530/EDM-19-0114Intractable hypercalcaemia during pregnancy and the postpartum secondary to pathogenic variants in CYP24A1Nirusha Arnold0Victor O’Toole1Tien Huynh2Howard C Smith3Catherine Luxford4Roderick Clifton-Bligh5Creswell J Eastman6Westmead Private Hospital, Westmead, Sydney, New South Wales, AustraliaWestmead Private Hospital, Westmead, Sydney, New South Wales, AustraliaWestmead Private Hospital, Westmead, Sydney, New South Wales, AustraliaWestmead Teaching HospitalKolling Institute of Medical Research, Royal North Shore Teaching Hospital, The University of Sydney, Sydney, New South Wales, AustraliaKolling Institute of Medical Research, Royal North Shore Teaching Hospital, The University of Sydney, Sydney, New South Wales, AustraliaWestmead Private Hospital, Westmead, Sydney, New South Wales, Australia; Westmead Teaching HospitalParathyroid-independent hypercalcaemia of pregnancy, due to biallelic loss of function of the P450 enzyme CYP24A1, the principal inactivator of 1,25(OH)2D results in hypervitaminosis D, hypercalcaemia and hypercalciuria. We report two cases of this disorder, with intractable hypercalcaemia, one occurring during gestation and into the postpartum, and the other in the postpartum period. Case 1, a 47-year-old woman with a twin pregnancy conceived by embryo transfer, presented with hypercalcaemia at 23 weeks gestation with subnormal serum parathyroid hormone (PTH) and normal serum 25-OH D levels. She was admitted to hospital at 31 weeks gestation with pregnancy-induced hypertension, gestational diabetes and increasing hypercalcaemia. Caesarean section at 34 weeks gestation delivered two healthy females weighing 2.13 kg and 2.51 kg. At delivery, the patient’s serum calcium level was 2.90 mmol/L. Postpartum severe hypercalcaemia was treated successfully with Denosumab 60 mg SCI, given on two occasions. CYP24A1 testing revealed she was compound heterozygous for pathogenic variants c.427_429delGAA, (p.Glu143del) and c.1186C>T, (p.Arg396Trp). Case 2, a 36-year-old woman presented 4 days after the delivery of healthy twins with dyspnoea, bradycardia, severe headaches, hypertension and generalized tonic-clonic seizures after an uneventful pregnancy. She was hypercalcaemic with a suppressed PTH, normal 25(OH)D, and elevated 1,25(OH)2D levels. Her symptoms partially responded to i.v. saline and corticosteroids in the short term but bisphosphonates such as Pamidronate and Zoledronic acid did not result in sustained improvement. Denosumab 120 mg SCI successfully treated the hypercalcaemia which resolved completely 2 months post-partum. CYP24A1 testing revealed she was homozygous for the pathogenic variant c.427_429delGAA, (p.Glu143del).https://edm.bioscientifica.com/view/journals/edm/2019/1/EDM19-0114.xml |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nirusha Arnold Victor O’Toole Tien Huynh Howard C Smith Catherine Luxford Roderick Clifton-Bligh Creswell J Eastman |
spellingShingle |
Nirusha Arnold Victor O’Toole Tien Huynh Howard C Smith Catherine Luxford Roderick Clifton-Bligh Creswell J Eastman Intractable hypercalcaemia during pregnancy and the postpartum secondary to pathogenic variants in CYP24A1 Endocrinology, Diabetes & Metabolism Case Reports |
author_facet |
Nirusha Arnold Victor O’Toole Tien Huynh Howard C Smith Catherine Luxford Roderick Clifton-Bligh Creswell J Eastman |
author_sort |
Nirusha Arnold |
title |
Intractable hypercalcaemia during pregnancy and the postpartum secondary to pathogenic variants in CYP24A1 |
title_short |
Intractable hypercalcaemia during pregnancy and the postpartum secondary to pathogenic variants in CYP24A1 |
title_full |
Intractable hypercalcaemia during pregnancy and the postpartum secondary to pathogenic variants in CYP24A1 |
title_fullStr |
Intractable hypercalcaemia during pregnancy and the postpartum secondary to pathogenic variants in CYP24A1 |
title_full_unstemmed |
Intractable hypercalcaemia during pregnancy and the postpartum secondary to pathogenic variants in CYP24A1 |
title_sort |
intractable hypercalcaemia during pregnancy and the postpartum secondary to pathogenic variants in cyp24a1 |
publisher |
Bioscientifica |
series |
Endocrinology, Diabetes & Metabolism Case Reports |
issn |
2052-0573 2052-0573 |
publishDate |
2019-11-01 |
description |
Parathyroid-independent hypercalcaemia of pregnancy, due to biallelic loss of function of the P450 enzyme CYP24A1, the principal inactivator of 1,25(OH)2D results in hypervitaminosis D, hypercalcaemia and hypercalciuria. We report two cases of this disorder, with intractable hypercalcaemia, one occurring during gestation and into the postpartum, and the other in the postpartum period. Case 1, a 47-year-old woman with a twin pregnancy conceived by embryo transfer, presented with hypercalcaemia at 23 weeks gestation with subnormal serum parathyroid hormone (PTH) and normal serum 25-OH D levels. She was admitted to hospital at 31 weeks gestation with pregnancy-induced hypertension, gestational diabetes and increasing hypercalcaemia. Caesarean section at 34 weeks gestation delivered two healthy females weighing 2.13 kg and 2.51 kg. At delivery, the patient’s serum calcium level was 2.90 mmol/L. Postpartum severe hypercalcaemia was treated successfully with Denosumab 60 mg SCI, given on two occasions. CYP24A1 testing revealed she was compound heterozygous for pathogenic variants c.427_429delGAA, (p.Glu143del) and c.1186C>T, (p.Arg396Trp). Case 2, a 36-year-old woman presented 4 days after the delivery of healthy twins with dyspnoea, bradycardia, severe headaches, hypertension and generalized tonic-clonic seizures after an uneventful pregnancy. She was hypercalcaemic with a suppressed PTH, normal 25(OH)D, and elevated 1,25(OH)2D levels. Her symptoms partially responded to i.v. saline and corticosteroids in the short term but bisphosphonates such as Pamidronate and Zoledronic acid did not result in sustained improvement. Denosumab 120 mg SCI successfully treated the hypercalcaemia which resolved completely 2 months post-partum. CYP24A1 testing revealed she was homozygous for the pathogenic variant c.427_429delGAA, (p.Glu143del). |
url |
https://edm.bioscientifica.com/view/journals/edm/2019/1/EDM19-0114.xml |
work_keys_str_mv |
AT nirushaarnold intractablehypercalcaemiaduringpregnancyandthepostpartumsecondarytopathogenicvariantsincyp24a1 AT victorotoole intractablehypercalcaemiaduringpregnancyandthepostpartumsecondarytopathogenicvariantsincyp24a1 AT tienhuynh intractablehypercalcaemiaduringpregnancyandthepostpartumsecondarytopathogenicvariantsincyp24a1 AT howardcsmith intractablehypercalcaemiaduringpregnancyandthepostpartumsecondarytopathogenicvariantsincyp24a1 AT catherineluxford intractablehypercalcaemiaduringpregnancyandthepostpartumsecondarytopathogenicvariantsincyp24a1 AT roderickcliftonbligh intractablehypercalcaemiaduringpregnancyandthepostpartumsecondarytopathogenicvariantsincyp24a1 AT creswelljeastman intractablehypercalcaemiaduringpregnancyandthepostpartumsecondarytopathogenicvariantsincyp24a1 |
_version_ |
1725070530955968512 |